Asset Details
Do you wish to reserve the book?
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Do you wish to request the book?
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
2013
Overview
Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti-CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.
Publisher
American Society for Clinical Investigation
Subject
Adjuvants, Immunologic - administration & dosage
/ Adjuvants, Immunologic - pharmacology
/ Animals
/ Antibodies, Monoclonal, Murine-Derived - administration & dosage
/ Brain Neoplasms - immunology
/ Cancer
/ Female
/ Humans
/ Immunologic Factors - administration & dosage
/ Lymphoma
/ Meningeal Neoplasms - immunology
/ Meningeal Neoplasms - secondary
/ Meningeal Neoplasms - therapy
/ Mice
/ Oligodeoxyribonucleotides - administration & dosage
/ Oligodeoxyribonucleotides - pharmacology
/ Receptors, OX40 - immunology
/ T-Lymphocytes, Regulatory - immunology
/ T-Lymphocytes, Regulatory - metabolism
/ Toll-Like Receptor 9 - agonists
/ Tumors
